Quince Therapeutics, Inc. (QNCX)
(Delayed Data from NSDQ)
$0.67 USD
-0.02 (-2.48%)
Updated Sep 3, 2024 10:04 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Quince Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 75 | 90 | 107 | 134 | 100 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 4 | 5 | 4 | 6 |
Total Current Assets | 77 | 94 | 112 | 138 | 106 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 1 |
Investments & Advances | 0 | 4 | 20 | 50 | 17 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 81 | 6 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 0 | 0 | 0 | 0 |
Total Assets | 168 | 104 | 133 | 189 | 124 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 5 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 9 | 13 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 10 | 3 | 14 | 17 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 13 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 54 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 83 | 3 | 15 | 17 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 402 | 389 | 355 | 319 | 185 |
Retained Earnings | -320 | -288 | -237 | -147 | -70 |
Other Equity | 3 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 85 | 101 | 119 | 172 | 115 |
Total Liabilities & Shareholder's Equity | 168 | 104 | 133 | 189 | 124 |
Total Common Equity | 85 | 101 | 119 | 172 | 115 |
Shares Outstanding | 42.80 | 36.10 | 29.80 | 29.50 | 26.80 |
Book Value Per Share | 1.99 | 2.79 | 3.98 | 5.84 | 4.31 |
Fiscal Year End for Quince Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 59 | 68 | 75 | 83 | 88 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 1 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 2 | 1 | 1 |
Total Current Assets | 63 | 70 | 77 | 85 | 89 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 62 | 80 | 81 | 0 | 0 |
Deposits & Other Assets | 9 | 8 | 8 | 0 | 0 |
Total Assets | 135 | 159 | 168 | 85 | 89 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 3 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 5 | 4 | 0 | 0 |
Total Current Liabilities | 10 | 10 | 10 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 5 | 5 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 14 | 14 | 13 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 58 | 54 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 88 | 85 | 83 | 2 | 2 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 404 | 403 | 402 | 393 | 392 |
Retained Earnings | -359 | -331 | -320 | -311 | -305 |
Other Equity | 1 | 2 | 3 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 47 | 74 | 85 | 83 | 87 |
Total Liabilities & Shareholder's Equity | 135 | 159 | 168 | 85 | 89 |
Total Common Equity | 47 | 74 | 85 | 83 | 87 |
Shares Outstanding | 43.20 | 43.20 | 42.80 | 36.30 | 36.30 |
Book Value Per Share | 1.09 | 1.72 | 1.99 | 2.29 | 2.39 |